Arcus Biosciences, Inc. Public Float
Arcus Biosciences, Inc. (RCUS) had Public Float of $565.88 million as of 2025-06-30, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Cover Page
dei:EntityPublicFloat · last filed 2026-02-25
- 2025-06-30: Entity Public Float $565.88M.
- 2024-06-28: Entity Public Float $825.14M.
- 2023-06-30: Entity Public Float $1.07B.
- 2022-06-30: Entity Public Float $1.30B.
| Period end | Entity Public Float |
|---|---|
| 2025-06-30 | $565.88M 10-K · filed 2026-02-25 |
| 2024-06-28 | $825.14M 10-K · filed 2025-02-25 |
| 2023-06-30 | $1.07B 10-K · filed 2024-02-21 |
| 2022-06-30 | $1.30B 10-K · filed 2023-02-28 |
| 2021-06-30 | $1.38B 10-K · filed 2022-02-23 |
| 2020-06-30 | $1.25B 10-K · filed 2021-02-25 |
| 2019-06-28 | $297.97M 10-K · filed 2020-03-05 |
| 2018-06-30 | $446.63M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |